🇺🇸 Erythropoietin in United States

3,052 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 543 reports (17.79%)
  2. Haemoglobin Decreased — 332 reports (10.88%)
  3. Off Label Use — 309 reports (10.12%)
  4. Pneumonia — 305 reports (9.99%)
  5. Diarrhoea — 291 reports (9.53%)
  6. Death — 284 reports (9.31%)
  7. Pyrexia — 258 reports (8.45%)
  8. Thrombocytopenia — 257 reports (8.42%)
  9. Neutropenia — 240 reports (7.86%)
  10. Fatigue — 233 reports (7.63%)

Source database →

Erythropoietin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Hematology approved in United States

Frequently asked questions

Is Erythropoietin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Erythropoietin in United States?

Nanjing First Hospital, Nanjing Medical University is the originator. The local marketing authorisation holder may differ — check the official source linked above.